← Back to headlines
Takeda's Rusfertide Receives FDA Priority Review for PV Treatment
Takeda Pharmaceutical Company has announced that its drug Rusfertide has been granted Priority Review by the FDA for the treatment of Polycythemia Vera (PV).
3 Apr, 18:02 — 3 Apr, 18:02
Sources
Showing 1 of 1 sources
